New York City-based Alta Fundamental Advisers initiated a new position in Chemours Company during the third quarter.
The fund reported 800,000 shares acquired with a net position change estimated at $12.67 million.
CC is now the fund’s fifth-largest holding, accounting for 6.2% of reported AUM.
New York City-based Alta Fundamental Advisers initiated a new position in The Chemours Company (NYSE:CC), acquiring 800,000 shares valued at an estimated $12.67 million, according to a November 13 SEC filing.
Alta Fundamental Advisers disclosed in a November 13 SEC filing that it established a new position in The Chemours Company during the third quarter. The fund reported owning 800,000 shares with a quarter-end value of $12.67 million. This marks the fund’s fifth-largest position out of 20 total holdings at quarter-end.
The new stake in CC makes up 5.41% of Alta Fundamental Advisers LLC’s reported U.S. equity assets under management.
Top holdings after the filing:
As of Monday, shares of The Chemours Company were priced at $12.02, down 32% over the past year and well underperforming the S&P 500’s 16% gain in the same period.
| Metric | Value |
|---|---|
| Revenue (TTM) | $5.84 billion |
| Net income (TTM) | ($320.00 million) |
| Dividend yield | 3% |
| Price (as of Monday) | $12.02 |
The Chemours Company is a leading global provider of performance chemicals, with a broad portfolio spanning titanium technologies, thermal and specialized solutions, advanced performance materials, and chemical solutions. The company leverages its scale and technical expertise to supply essential materials that enable a wide range of industrial and consumer applications. Chemours’ strong market presence and diversified end-market exposure support its competitive positioning within the specialty chemicals sector.
What matters for long-term investors is not that this position was initiated, but how large it is relative to everything else. At more than 5% of reported assets and immediately ranking among the fund’s top five holdings, this is a statement position, not a speculative add. That matters because this portfolio is otherwise concentrated in deeply cyclical and out-of-favor names, suggesting a willingness to lean into discomfort rather than chase momentum.
The fundamentals help explain the calculus. In the third quarter, The Chemours Company generated $1.5 billion in revenue, flat year over year, but swung to a net income of $60 million from a $32 million loss a year earlier. Adjusted EBITDA came in at $195 million, and free cash flow reached $105 million, a 54% conversion rate. Strength in Thermal and Specialized Solutions, where Opteon refrigerant sales jumped 80%, helped offset weakness in titanium dioxide and advanced materials. Ultimately, this is not a clean story, but it is a cash-generating one with identifiable levers.
13F: A quarterly report filed by institutional investment managers disclosing their equity holdings to the U.S. Securities and Exchange Commission (SEC).
Assets under management (AUM): The total market value of assets that an investment firm manages on behalf of clients.
Dividend yield: Annual dividends paid by a company divided by its share price, shown as a percentage.
Forward P/E: Price-to-earnings ratio using forecasted earnings for the next 12 months.
Trailing EV/EBITDA: Enterprise value divided by earnings before interest, taxes, depreciation, and amortization over the past 12 months.
Position: The amount of a particular security or asset held by an investor or fund.
Stake: The ownership interest or share an investor holds in a company.
Quarter-end: The last day of a fiscal quarter, used as a reference point for financial reporting.
Performance chemicals: Specialized chemical products designed for specific industrial or commercial applications.
End-market: The final industry or sector where a product or service is ultimately used.
TTM: The 12-month period ending with the most recent quarterly report.
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 972%* — a market-crushing outperformance compared to 193% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
*Stock Advisor returns as of December 22, 2025.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool recommends USA Today. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
